ai-native-pharma
(2)
David Steinberg
David Steinberg is Chief Business Officer at Formation Bio, an AI-native pharmaceutical company in New York, where he runs in- and out-licensing and pipeline strategy. A serial biotech company builder, he co-founded PureTech Health and served as its Chief Innovation Officer, was a General Partner at Longwood Fund, and founded or led a string of NASDAQ-listed and venture-backed companies including Pyxis Oncology, Vor Biopharma, Vedanta Biosciences and Be Biopharma. He pairs a Cornell biology degree with a University of Chicago Booth MBA and a career that began in R&D and strategy consulting.
Formation Bio
Formation Bio is a New York-based, AI-native pharmaceutical company that acquires and in-licenses clinical-stage drug candidates and runs them through a proprietary, technology-driven development platform to bring treatments to patients faster and at lower cost. Formerly known as TrialSpark, the company rebranded in December 2023 and raised a $372M Series D in June 2024 led by Andreessen Horowitz and Sanofi. It pairs in-house drug selection expertise with AI tools for trial design, recruitment, regulatory writing, and safety monitoring, and partnered with OpenAI and Sanofi to build purpose-built AI agents for drug development.